Volex Raises FY2027 Profit Outlook After Strong Trading and Main Market Transition

Engineers

Volex (LSE:VLX) has upgraded its profit expectations for the 2027 financial year after delivering strong revenue growth during the opening months of the period, supported by demand across each of its five principal end-markets.

For the four months ended 31 July, the specialist power and data transmission manufacturer recorded constant-currency organic revenue growth of 28%. Complex Industrial Technology was a major contributor, with data centre customers continuing to place orders at elevated levels.

EV and Electrification also performed strongly, while Consumer Electricals, Off-Highway and Medical each generated solid growth, giving Volex a broad-based contribution across its portfolio.

Management said sequential comparisons provide a clearer indication of the underlying momentum in the business. Average monthly revenue during the four-month period was approximately 8% higher than the average recorded during the second half of FY2026.

Alongside the increase in sales, continued discipline around operating expenses is contributing to improved underlying operating margins. The combination of higher volumes and controlled costs is allowing Volex to benefit from increased operating leverage.

The company has also completed the acquisition of the remaining interest in Kepler SignalTek, expanding its capabilities within the medical sector. The transaction extends Volex’s offering into patient-to-device applications and is expected to support further margin improvement as the business is integrated.

Main Market Move Raises Volex’s Investor Profile

Volex recently completed its move from AIM to the Main Market of the London Stock Exchange, with its shares admitted to the Official List. The board believes the transition more accurately reflects the company’s current scale and maturity while potentially making the shares accessible to a broader range of investors.

Following the strong start to FY2027 and the benefits of operating leverage, the board now expects underlying operating profit for the full year to exceed current market expectations.

The upgraded outlook provides further support for Volex’s medium-term strategy, which is focused on generating growth across structurally attractive markets while increasing margins and expanding its global manufacturing capabilities.

Strong demand, particularly from data centre and electrification customers, combined with portfolio expansion in medical applications, gives the company several potential drivers of future growth. The Main Market transition could also increase Volex’s visibility among larger institutional investors.

The company’s wider outlook is supported by revenue growth, improving profitability and a strengthening balance sheet, although weaker cash-flow conversion remains an area to monitor. Technical indicators are less favourable, with the shares trading below important moving averages, although oversold readings provide some balance to the weaker trend.

Valuation appears relatively reasonable rather than heavily discounted, while management’s stronger guidance and recent operational momentum provide additional support. Customer concentration and working-capital requirements nevertheless remain important considerations as the business continues to expand.

About Volex plc

Volex plc is a UK-headquartered integrated manufacturer specialising in critical power and data transmission products for international customers.

The group serves five principal markets: Complex Industrial Technology, Consumer Electricals, EV and Electrification, Medical and Off-Highway. Its products are supplied to original equipment manufacturers and electronic manufacturing services companies around the world.

Volex operates 23 manufacturing facilities across 25 countries and employs approximately 12,500 people. Its global footprint allows the company to support major industrial and technology customers while participating in structural growth areas including data centre infrastructure, electrification and medical technology.

The company recently transferred its shares from AIM to the Main Market of the London Stock Exchange. The move reflects the increased scale and maturity of the group and is intended to broaden its potential investor base as Volex pursues further growth and margin expansion.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *